C-RAD will be conducting a user meeting prior to ASTRO's 57th Annual Meeting in San Antonio, Texas, USA, on October 17, 2015. The meeting will be conducted in cooperation with the University of Texas Health Science Center San Antonio (UTHSCSA), and will focus on clinical treatment using C-RAD’s Catalyst HD™ for breast cancer treatment and for stereotactic treatments.
Invited guests to the event will be able to listen to clinical speakers from the Cancer Therapy & Research Center the University of Texas, who will be joined by representatives of the C-RAD management and R&D teams, as well as other members of the C-RAD Research Fellow Program. Topics will include developments necessary for stereotactic body radiotherapy (SBRT).
The Center at the UTHSC San Antonio recently joined the Research Fellow Program, with the intention of contributing to the development of C-RAD’s Catalyst HD for stereotactic radiotherapy.
C-RAD established its Research Fellow Program in 2014 to involve leading cancer research centers in improving the radiotherapy process with current C-RAD products, and to develop even more advanced solutions based on clinical practice. Membership is from 1-3 years and involves direct collaboration with C-RAD’s R&D group.
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 39. C-RAD’s business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit www.c-rad.com.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email email@example.com